The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination-Reference-Cited by-同舟云学术

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

Published:2010-09-13 Issue:6 Volume:46 Page:784-789
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Jordan K,Jahn F,Jahn P,Behlendorf T,Stein A,Ruessel J,Kegel T,Schmoll H-J

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2010205.pdf

Reference25 articles.

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203–208.

2. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189–195.

3. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005; 13: 112–116.

4. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932–2947.

5. Roila F, Herrstedt J, Aapro M . Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 (Suppl 5): v232–v243.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation;Clinical Hematology International;2022-07-11

2. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study;Annals of Hematology;2022-06-06

3. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review;Cancer Chemotherapy and Pharmacology;2022-05-30

4. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience;Supportive Care in Cancer;2021-08-04

5. Clinical Pharmacology Research for Promoting Individualized Cancer Chemotherapy;YAKUGAKU ZASSHI;2019-06-01